Immunotherapy plus chemotherapy for advanced endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new medicine called QL1706 (a type of immunotherapy that helps your immune system fight cancer) combined with chemotherapy for women with advanced or recurrent endometrial cancer that has not been treated before. The goal is to see if this combination can shrink tumors and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 75 years old.
- You must have stage III or IV endometrial cancer that has come back or spread, and you have not had any previous chemotherapy or other whole-body treatment for it.
- You need to have at least one tumor that can be measured on a scan (like a CT scan).
- You must be able to perform daily activities (ECOG score of 0 or 1).
- You cannot have certain types of uterine sarcomas (like carcinosarcoma or leiomyosarcoma).
- You must be willing to use contraception during the study if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests a combination of immunotherapy (adebrelimab) and chemotherapy (carboplatin/paclitaxel), followed by more immunotherapy, with or without an additional targeted drug (apatinib), for advanced or recurrent endometrial cancer. It aims to see if adding the targeted drug improves outcomes.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests whether adding a targeted drug (fruquintinib) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced or recurrent endometrial cancer that is pMMR. It may help control the cancer for a longer time.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Recurrent or Metastatic Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.